• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Product › Details

clinical research

	Next higher product group	pharma services

Record changed: 2020-12-26

Advertisement

More documents for clinical research

• [1] Metagenomi Inc.. (4/7/21). "Press Release: Metagenomi Announces the Addition of Leading Immuno-oncology Clinical Research Experts to Its Scientific Advisory Board". Emeryville, CA....
• [2] Valneva S.E.. (4/6/21). "Press Release: Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001". Saint-Herblain....
• [3] Enterome S.A.. (3/24/21). "Press Release: Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors"....
• [4] Vaccitech Ltd.. (3/17/21). "Press Release: Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results". Oxford....
• [5] Excelya S.A.S.. (3/8/21). "Press Release: Nathalie Doize Appointed Director of Operations & Rudolph Rosenberg Appointed Chief Financial Officer". Boulogne-Billancourt....
• [6] Immunocore Holdings plc. (2/19/21). "Press Release: Immunocore’s Tebentafusp Granted Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma from FDA". Oxfordshire, Conshohocken, PA & Rockville, MD....
• [7] InteRNA Technologies B.V.. (2/16/21). "Press Release: InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors". Utrecht....
• [8] CureVac N.V.. (2/12/21). "Press Release: CureVac Initiates Rolling Submission with European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV". Tübingen & Boston, MA....
• [9] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
• [10] Catalym GmbH. (1/28/21). "Press Release: Catalym Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.